Document is current
Any future updates will be listed below
-
Authors
Kobayashi, Satoshi
Tezuka, Shun
Yamachika, Yui
Tsunoda, Shotaro
Nagashima, Shuhei
Tozuka, Yuichiro
Fukushima, Taito
Morimoto, Manabu
Ueno, Makoto
Furuse, Junji
Maeda, Shin
-
Funding
Funding for this research was provided by:
the Kanagawa Prefectural Cancer foundation
- License Information
-
More Information
Article History
Received: 31 October 2022
Accepted: 15 February 2023
First Online: 21 February 2023
Declarations
:
: Each patient provided written informed consent for the FOLFOX treatment. This study was conducted in accordance with the Declaration of Helsinki, Ethical Guidance for Studies in Life Science and Medical Science in Humans (by the Ministry of Education, Culture, Sports, Science and Technology, Japan, and the Ministry of Health, Labour and Welfare, Japan). Informed consent was waived due to the retrospective nature of the study, and the study design was approved by the Institutional Review Board of Kanagawa Cancer Center. The study participants were given the choice to opt out of having any information published.
: Not applicable.
: The authors declare that they have no competing interests.
